1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration.
N Engl J Med 2006;355:1419-1431.
2. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Ophthalmology 2006;113:363-372.e5.
3. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Am J Ophthalmol 2007;143:566-583.
4. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
Ophthalmology 2012;119:1388-1398.
5. Kwon YH, Lee DK, Kim HE, Kwon OW. Predictive findings of visual outcome in spectral domain optical coherence tomography after ranibizumab treatment in age-related macular degeneration.
Korean J Ophthalmol 2014;28:386-392.
6. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
N Engl J Med 2006;355:1432-1444.
7. Cho HJ, Koh KM, Kim HS, et al. Anti-vascular endothelial growth factor monotherapy in the treatment of submacular hemorrhage secondary to polypoidal choroidal vasculopathy.
Am J Ophthalmol 2013;156:524-531.e1.
8. Iacono P, Parodi MB, Introini U, et al. Intravitreal ranibizumab for choroidal neovascularization with large submacular hemorrhage in age-related macular degeneration.
Retina 2014;34:281-287.
9. Shienbaum G, Garcia Filho CA, Flynn HW Jr, et al. Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy.
Am J Ophthalmol 2013;155:1009-1013.
10. Stifter E, Michels S, Prager F, et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.
Am J Ophthalmol 2007;144:886-892.
11. Kim JH, Chang YS, Kim JW, et al. Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization.
Ophthalmology 2014;121:926-935.
12. McKibbin M, Papastefanou V, Matthews B, et al. Ranibizumab monotherapy for sub-foveal haemorrhage secondary to choroidal neovascularisation in age-related macular degeneration.
Eye (Lond) 2010;24:994-998.
13. Avery RL, Fekrat S, Hawkins BS, Bressler NM. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration.
Retina 1996;16:183-189.
14. Bressler NM, Bressler SB, Childs AL, et al. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13.
Ophthalmology 2004;111:1993-2006.
15. Scupola A, Coscas G, Soubrane G, Balestrazzi E. Natural history of macular subretinal hemorrhage in age-related macular degeneration.
Ophthalmologica 1999;213:97-102.
16. Bennett SR, Folk JC, Blodi CF, Klugman M. Factors prognostic of visual outcome in patients with subretinal hemorrhage.
Am J Ophthalmol 1990;109:33-37.
17. Hwang JU, Yang SJ, Yoon YH, et al. Recurrent submacular hemorrhage in patients with neovascular age-related macular degeneration.
Retina 2012;32:652-657.
18. Holladay JT. Visual acuity measurements.
J Cataract Refract Surg 2004;30:287-290.
19. Kang SW, Chung SE, Shin WJ, Lee JH. Polypoidal choroidal vasculopathy and late geographic hyperfluorescence on indocyanine green angiography.
Br J Ophthalmol 2009;93:759-764.
20. Kim JH, Kang SW, Kim TH, et al. Structure of polypoidal choroidal vasculopathy studied by colocalization between tomographic and angiographic lesions.
Am J Ophthalmol 2013;156:974-980.e2.
21. Sato T, Kishi S, Watanabe G, et al. Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy.
Retina 2007;27:589-594.
22. CATT Research Group. Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
N Engl J Med 2011;364:1897-1908.
23. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990;10:1-8.
24. Ciardella AP, Donsoff IM, Huang SJ, et al. Polypoidal choroidal vasculopathy.
Surv Ophthalmol 2004;49:25-37.
25. Coscas G, Yamashiro K, Coscas F, et al. Comparison of exudative age-related macular degeneration subtypes in Japanese and French Patients: multicenter diagnosis with multimodal imaging.
Am J Ophthalmol 2014;158:309-318.e2.
26. Sho K, Takahashi K, Yamada H, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics.
Arch Ophthalmol 2003;121:1392-1396.
27. Byeon SH, Lee SC, Oh HS, et al. Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients.
Jpn J Ophthalmol 2008;52:57-62.
28. Koh AH. Expert PCV Panel. Chen LJ, et al. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment.
Retina 2013;33:686-716.
29. Oishi A, Kojima H, Mandai M, et al. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results.
Am J Ophthalmol 2013;156:644-651.
30. Lee SY, Kim JG, Joe SG, et al. The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy.
Korean J Ophthalmol 2008;22:92-99.
31. Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.
Retina 2012;32:1453-1464.
32. Yoneyama S, Sakurada Y, Mabuchi F, et al. Genetic and clinical factors associated with reticular pseudodrusen in exudative age-related macular degeneration.
Graefes Arch Clin Exp Ophthalmol 2014;252:1435-1441.
33. Fujimura S, Ueta T, Takahashi H, et al. Characteristics of fundus autofluorescence and drusen in the fellow eyes of Japanese patients with exudative age-related macular degeneration.
Graefes Arch Clin Exp Ophthalmol 2013;251:1-9.
34. Kim SW, Oh J, Kwon SS, et al. Comparison of choroidal thickness among patients with healthy eyes, early age-related maculopathy, neovascular age-related macular degeneration, central serous chorioretinopathy, and polypoidal choroidal vasculopathy.
Retina 2011;31:1904-1911.